Amplia Therapeutics (ATX.AX) Earnings Analysis
Amplia Therapeutics (ATX.AX) has no confirmed upcoming earnings date. Trailing P/E -8.08.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ATX.AX next report earnings?
No confirmed upcoming earnings date is currently scheduled for ATX.AX. This page updates as the calendar is published.
ATX.AX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-29 | -0.0069 AUD | n/a | n/a | n/a |
| 2026-05-28 | -0.0104 AUD | n/a | n/a | n/a |
| 2024-11-20 | -0.01109 AUD | n/a | n/a | n/a |
ATX.AX valuation and analyst view
| Trailing P/E | -8.08 |
|---|---|
| Trailing EPS | -0.01502 AUD |
| Price / book | 1.75 |
| Dividend yield | 0.00% |
| Market cap | 0.07B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Amplia Therapeutics (ATX.AX)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for ATX.AX. This page updates as the calendar is published.
Did ATX.AX beat earnings last quarter?
Consensus estimate data was not available for ATX.AX's 2026-05-29 report.
What is ATX.AX's current P/E ratio and EPS?
ATX.AX trades at a trailing P/E of -8.08 on trailing EPS of -0.015021590679300648 AUD.
What do analysts rate ATX.AX?
ATX.AX has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.